{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:11:04Z","timestamp":1761513064170},"reference-count":41,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.3892\/etm.2011.398","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T16:24:18Z","timestamp":1322843058000},"page":"171-180","source":"Crossref","is-referenced-by-count":5,"title":["Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma"],"prefix":"10.3892","volume":"3","author":[{"given":"YONGPING","family":"YANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YINYING","family":"LU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUNPING","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WENLIN","family":"BAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIANHUI","family":"QU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAN","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIUJUAN","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LINJING","family":"AN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIN","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHEN","family":"ZENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIN","family":"LOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIYUN","family":"LV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"key20180108121027_b1-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"key20180108121027_b2-etm-03-02-0171","first-page":"1","article-title":"Perspective of clinical onology from the viewpoint of liver cancer studies","volume":"29","author":"Tang","year":"2009","journal-title":"Tumor (China)"},{"key":"key20180108121027_b3-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2003.11.137","article-title":"The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time","volume":"21","author":"Yoo","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108121027_b4-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180108121027_b5-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","article-title":"Hepatocellular carcinoma: epidemiology, risk factors, and screening","volume":"25","author":"Sherman","year":"2005","journal-title":"Semin Liver Dis"},{"key":"key20180108121027_b6-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"key20180108121027_b7-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"key20180108121027_b8-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/jhep.2002.32089","article-title":"Prognosis prediction and treatment strategy in hepatocellular carcinoma","volume":"35","author":"Bruix","year":"2002","journal-title":"Hepatology"},{"key":"key20180108121027_b9-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"key20180108121027_b10-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1746.2007.05112.x","article-title":"Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area","volume":"23","author":"Park","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"key20180108121027_b11-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/lt.20034","article-title":"The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma","volume":"10","author":"Llovet","year":"2004","journal-title":"Liver Transpl"},{"key":"key20180108121027_b12-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108121027_b13-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108121027_b14-etm-03-02-0171","first-page":"779","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"2","author":"Furuse","year":"2008","journal-title":"Biologics"},{"key":"key20180108121027_b15-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1148\/radiol.2442061005","article-title":"Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice","volume":"244","author":"Hakim\u00e9","year":"2007","journal-title":"Radiology"},{"key":"key20180108121027_b16-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jso.20712","article-title":"Serum cytokine levels in response to hepatic cryoablation","volume":"95","author":"Osada","year":"2007","journal-title":"J Surg Oncol"},{"key":"key20180108121027_b17-etm-03-02-0171","first-page":"323","article-title":"Cryosurgery for colorectal liver metastases","volume":"48","author":"Poston","year":"2001","journal-title":"Hepatogastroenterol"},{"key":"key20180108121027_b18-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1148\/radiology.202.3.9051005","article-title":"Hepatic cryosurgery with intraoperative US guidance","volume":"202","author":"Lee","year":"1997","journal-title":"Radiology"},{"key":"key20180108121027_b19-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1148\/radiol.2361040533","article-title":"Hepatic hemorrhage caused by percutaneous tumor ablation: radiofrequency ablation versus cryoablation in a porcine model","volume":"236","author":"Shock","year":"2005","journal-title":"Radiology"},{"key":"key20180108121027_b20-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1148\/radiol.2431052133","article-title":"Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience","volume":"243","author":"Atwell","year":"2007","journal-title":"Radiology"},{"key":"key20180108121027_b21-etm-03-02-0171","first-page":"554","article-title":"Cryoablation of malignant liver tumor: results of a single center study","volume":"4","author":"Jungraithmayr","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key20180108121027_b22-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jjco\/hym025","article-title":"Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan Criteria","volume":"34","author":"Yamamoto","year":"2007","journal-title":"Jpn J Clin Ocncol"},{"key":"key20180108121027_b23-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"key20180108121027_b24-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"key20180108121027_b25-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10585-009-9283-6","article-title":"Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study","volume":"26","author":"Wang","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"key20180108121027_b26-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1200\/JCO.2002.07.089","article-title":"Tumor microvessel density as a predictor recurrence after resection of hepatocellular carcinoma: a prospective study","volume":"20","author":"Poon","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108121027_b27-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"key20180108121027_b28-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6604784","article-title":"Molecular therapy for the treatment of hepatocellular carcinoma","volume":"100","author":"Greten","year":"2009","journal-title":"Br J Cancer"},{"key":"key20180108121027_b29-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"231239","DOI":"10.1016\/S0001-2092(06)63151-7","article-title":"Cryosurgical ablation of unresectable hepatic tumors","volume":"64","author":"Zuro","year":"1996","journal-title":"AORN J"},{"key":"key20180108121027_b30-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00534-009-0124-4","article-title":"Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma","volume":"16","author":"Shimizu","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"key20180108121027_b31-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00432-008-0496-x","article-title":"Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcnoma patients in a Hepatitis B virus-endemic area","volume":"135","author":"Shim","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180108121027_b32-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","article-title":"Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis","volume":"14","author":"Pinter","year":"2009","journal-title":"Oncologist"},{"key":"key20180108121027_b33-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Kane","year":"2009","journal-title":"Oncologist"},{"key":"key20180108121027_b34-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"key20180108121027_b35-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis","volume":"43","author":"W\u00f6rns","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"key20180108121027_b36-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi","year":"2010","journal-title":"Oncologist"},{"key":"key20180108121027_b37-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Schramm","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key20180108121027_b38-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","article-title":"Angiogenesis and hepatocellular carcinoma","volume":"41","author":"Semela","year":"2004","journal-title":"J Hepatol"},{"key":"key20180108121027_b39-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"key20180108121027_b40-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.canlet.2009.05.014","article-title":"Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells","volume":"285","author":"Li","year":"2009","journal-title":"Cancer Lett"},{"key":"key20180108121027_b41-etm-03-02-0171","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/ijc.24272","article-title":"Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells","volume":"124","author":"Li","year":"2009","journal-title":"Int J Cancer"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2011.398\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T05:53:07Z","timestamp":1713160387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2011.398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.3892\/etm.2011.398"],"URL":"https:\/\/doi.org\/10.3892\/etm.2011.398","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}